Apogee Therapeutics, Inc.
APGE
Classement en actions
#2358
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Prix de l'action
$135.07
Dernière synchronisation: 2026-09-04
Capitalisation boursière
$8.36B
Changement (1 jour)
0.00%
Changement (1 an)
144.91%
Pays
US
Échange Apogee Therapeutics, Inc. (APGE)
Catégorie
Healthcare
EPS pour Apogee Therapeutics, Inc. (APGE)
EPS au June 2026 TTM : $-4.34
Selon les derniers rapports financiers et le cours de l'action de Apogee Therapeutics, Inc., l’EPS actuel de la société (TTM) est de $-4.34. À la fin de 2023, la société avait un EPS de $-1.66 une augmentation par rapport à celui de 2022, qui était de $-0.79.
Historique de l'EPS de Apogee Therapeutics, Inc. de 2022 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
